Mitochondrially Targeted p53 Has Tumor Suppressor Activities <i>In vivo</i>
Flaminia Talos(Stony Brook University), Ute M. Moll(Stony Brook University)
Cited by 74
Related Papers
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
|Proceedings of the National Academy of Sciences|1992|580
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.
|Proceedings of the National Academy of Sciences|1995|433
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
|Cell Death and Differentiation|2011|331
ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
|The Journal of Experimental Medicine|2002|317
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
|The Journal of Experimental Medicine|2012|121